ReviewJournal of nuclear medicine : official publication, Society of Nuclear Medicine2016
Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer.
Review in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 47 citations in OpenAlex.
- Utility ofEuropean journal of nuclear medicine and molecular imaging · 2017Trial
- Uterine Uptake of Estrogen and Progestogen-Based Radiotracers in Rhesus Macaques with Endometriosis.Molecular imaging and biology · 2024Article
- The Potentiality of Prostate-Specific Antigen as a Prognostic Biomarker in Breast Cancer.Cureus · 2023Article
- Review
- Radioiodinated Ethinylestradiol Derivatives for Estrogen Receptor Targeting Breast Cancer Imaging.ACS medicinal chemistry letters · 2022Article
- ABO BLOOD GROUP GENOTYPES IN WOMEN WITH BREAST CANCER.Acta clinica Croatica · 2022Article
- Quantitation of multiple injection dynamic PET scans: an investigation of the benefits of pooling data from separate scans when mapping kinetics.Physics in medicine and biology · 2021Article
- ZR-75-1 breast cancer models to study the utility ofTranslational cancer research · 2021Article
- The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[Nuclear medicine and biology · 2021Review
- Concepts for design and analysis of receptor radiopharmaceuticals: The Receptor-Binding Radiotracers series of meetings provided the foundation.Nuclear medicine and biology · 2021Review
- Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Review
- Development of Radiotracers for Breast Cancer-The Tumor Microenvironment as an Emerging Target.Cells · 2020Review
- Review
- Review
- Recent Advances in Nuclear Imaging of Receptor Expression to Guide Targeted Therapies in Breast Cancer.Cancers · 2019Review
- Advances in PET Diagnostics for Guiding Targeted Cancer Therapy and Studying In Vivo Cancer Biology.Current pathobiology reports · 2019Article
- Clinical Potential of Estrogen and Progesterone Receptor Imaging.PET clinics · 2018Review
- Multifunctionalized biocatalytic P22 nanoreactor for combinatory treatment of ER+ breast cancer.Journal of nanobiotechnology · 2018Article
- Determination of binding affinity of molecular imaging agents for steroid hormone receptors in breast cancer.American journal of nuclear medicine and molecular imaging · 2018Article
- Harnessing Preclinical Molecular Imaging to Inform Advances in Personalized Cancer Medicine.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 1 country.
Funding
Abstract
Estrogen receptor alpha (ERα) and progesterone receptor (PR) are important steroid hormone receptor biomarkers used to determine prognosis and to predict benefit from endocrine therapies for breast cancer patients. Receptor expression is routinely measured in biopsy specimens using immunohistochemistry, although such testing can be challenging, particularly in the setting of metastatic disease. ERα and PR can be quantitatively assayed noninvasively with PET. This approach provides the opportunity to assess receptor expression and function in real time, within the entire tumor, and across distant sites of metastatic disease. This article reviews the current evidence of ERα and PR PET imaging as predictive and early-response biomarkers for endocrine therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.